Who is the manufacturer?

Shijiazhuang No.4 Pharmaceutical Co., Ltd., a large-sized foreign invested enterprise established in 1948.

What are the payment terms?

Payment can be made via Letter of Credit (LC) or Telegraphic Transfer (T/T).

What are the typical lead times for orders?

The average lead time is one month, particularly during peak seasons.

Ringer Lactate Injection Medicine Infusion

Name: Ringer Lactate Injection Medicine Infusion
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2038256712

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

20,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Function

Regulating Water and Salt, Electrolyte and Acid-Base Balance of Medicine

Certification

GMP, Bp/USP/Cp

Grade Standard

Medicine Grade

Type

Chemical Reagent

State

Liquid

Volatile

Not Volatile

Transport Package

500ml Plastic Bottle, 30 Bottles/Carton

Specification

500ml plastic bottle

Origin

China

HS Code

30049090

Production Capacity

1000000pieces/Year

Key features

GMP Certified Quality: Manufactured under GMP, BP/USP/CP standards ensuring high pharmaceutical grade.

Electrolyte Balance: Regulates water, salt, electrolyte, and acid-base balance in the body.

Corrects Acidosis: Effective for treating metabolic acid toxicosis and dehydration.

Trusted Manufacturer: Produced by Shijiazhuang No.4 Pharmaceutical, established in 1948.

Large Scale Production: Annual output exceeds 1200 million bottles with advanced packaging.

Global Export Experience: Products exported to South America, Africa, Asia, and other regions since 2002.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.